BOSTON, MA — The 3D-Bioplotter business and associated assets have joined Linton Lifesciences, bringing one of the most established extrusion-based biofabrication platforms into a company focused on advancing biomaterials, bioprinting, and next-generation medical products.

The transition includes Bioplotter intellectual property and technical know-how, equipment and spare-parts inventory, and support responsibilities for the platform’s existing customer base. Since its introduction in 2000, the 3D-Bioplotter has become an established tool in biofabrication, particularly in reference to producing patient implants, with systems deployed at research institutions, hospitals, and life sciences companies around the world.

The platform has supported decades of research across tissue engineering, regenerative medicine, medical devices, and biomaterials development. Its ability to process a broad range of materials, including hydrogels, thermoplastics, ceramics, and cell-containing formulations, has made it a versatile tool for scientists and engineers developing increasingly complex biological and medical technologies.

Beyond research, the 3D-Bioplotter has also demonstrated its relevance to commercial medical-product development, including its use in manufacturing an FDA 510(k)-cleared device.

Under Linton, the platform is entering a new phase.

Linton plans to continue Bioplotter sales, technical support, and customer engagement while investing in the platform’s future development. Carlos Carvalho, who brings extensive experience with the technology, is joining Linton as part of the transition, helping preserve technical expertise and continuity for the global installed base.

The addition of the 3D-Bioplotter brings together complementary capabilities. Linton’s work in medical implants, perfused tissue models, and advanced biomaterials creates opportunities to build upon the Bioplotter’s established manufacturing capabilities. By working with researchers, material developers, industry partners, and medical-product manufacturers, the company aims to expand the platform beyond a standalone research instrument into a broader ecosystem of biofabrication hardware, materials, applications, and production workflows.

The strategy reflects a broader evolution in biofabrication. As the field matures, attention is shifting from demonstrating what can be printed toward establishing the reproducibility, scalability, and reliability needed to translate promising technologies into practical research and manufacturing applications.

Established biofabrication platforms such as the 3D-Bioplotter provide a strong foundation for advancing the next generation of tissue models, biomaterials, and medical technologies. With an extensive installed base, decades of accumulated technical expertise, and compatibility with a broad range of biomaterials, the platform offers an opportunity to accelerate innovation while leveraging proven manufacturing capabilities.

For Linton Lifesciences, the acquisition represents a strategic step toward building an integrated biofabrication ecosystem. By combining established manufacturing technology with emerging biomaterials, advanced biological models, and medical device development, Linton aims to expand the platform’s capabilities, accelerate the translation of research into practical applications, and support the development of next-generation medical products.

About Linton Lifesciences

Linton Lifesciences is a Boston headquartered biofabrication company focused on bridging biofabrication for the benefit of patient care. Linton’s mission is to develop biofabrication platforms, tissue models, and medical implants to help us live longer, healthier, and more rewarding lives.

Leave a Reply

Trending